- Home
- IDR vs INBX Comparison
IDR vs INBX Comparison
Compare IDR & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IDR | INBX |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 671.6M | 1.1B |
| IPO Year | 2000 | 2024 |
Fundamental Metrics
Financial Performance| Metric | IDR | INBX |
|---|---|---|
| Price | $38.75 | $71.69 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $17.50 | N/A |
| AVG Volume (30 Days) | ★ 256.3K | 133.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 644.44 | ★ 649.90 |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $25,765,373.00 | $200,000.00 |
| Revenue This Year | $55.62 | $563.00 |
| Revenue Next Year | $23.93 | N/A |
| P/E Ratio | $73.86 | ★ N/A |
| Revenue Growth | ★ 88.66 | N/A |
| 52 Week Low | $10.61 | $10.81 |
| 52 Week High | $54.70 | $94.57 |
Technical Indicators
Market Signals| Indicator | IDR | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 47.17 | 42.33 |
| Support Level | $38.13 | $28.54 |
| Resistance Level | $41.08 | $85.97 |
| Average True Range (ATR) | 2.57 | 4.54 |
| MACD | -0.12 | -0.90 |
| Stochastic Oscillator | 30.58 | 26.10 |
Price Performance
Historical ComparisonAbout IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.